No Data
No Data
Amneal Pharmaceuticals (NASDAQ:AMRX) Doubles Its Share Value and Trade at a Discount
Teva Focus of FTC Investigation Over Inhaler Patents
Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments
Amneal Pharmaceuticals (AMRX) said Monday that it has expanded its biosimilar portfolio to eight by adding ADL018, a proposed biosimilar of Novartis' (NVS) Xolair, or omalizumab, to its pipeline. The
Express News | Kashiv Biosciences, LLC - Financial Terms of Transaction Not Disclosed
Express News | Kashiv Biosciences Enters Into Exclusive Licensing Agreement With Amneal for Commercialization of a Proposed Biosimilar to Xolair® (Omalizumab)
Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $8
Barclays analyst Balaji Prasad maintains $Amneal Pharmaceuticals(AMRX.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 45.4% a